Transaction DateRecipientSharesTypePriceValue
3rd September 2020Scott E. Royer500Exercise of derivative$3.90$1,950.00
27th July 2020John E. Leonard1,000Exercise of derivative$3.90$3,900.00
10th July 2020Albert Friedberg1,126,760Open or private purchase$3.55$3,999,998.00
30th March 2020Albert Friedberg5,000Open or private purchase$4.06$20,300.00
27th March 2020Albert Friedberg4,000Open or private purchase$4.18$16,720.00
26th March 2020Albert Friedberg1,000Open or private purchase$4.44$4,440.00
24th March 2020Albert Friedberg2,000Open or private purchase$4.40$8,800.00
20th March 2020Albert Friedberg2,000Open or private purchase$4.31$8,620.00
19th March 2020Albert Friedberg4,000Open or private purchase$4.15$16,600.00
17th March 2020Albert Friedberg3,440Open or private purchase$4.00$13,760.00
Vaccinex logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Vaccinex, Inc. is a clinical-stage biotechnology company. Its products pipeline include SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997.

Ticker: VCNX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1205922
Employees: 49
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags